Japanese pharmaceutical corporation Astellas Pharma Inc., (TYO: 4503) has announced its financial results for the first three quarters of its fiscal year 2023, concluding on December 31, 2023. The company has experienced a modest 2.1% year-on-year (YOY) increase in global revenues, totaling JPY 1,189 billion (USD 8 billion) for the nine-month period.
Astellas’ flagship products have shown consistent growth trajectories, with the prostate cancer treatment Xtandi (enzalutamide) marking a 9.4% increase in sales to JPY 560 billion (USD 3.77 billion). The urothelial cancer therapy Padcev (enfortumab vedotin) has seen a significant surge, with a 68.9% rise in revenue to JPY 55.6 billion (USD 370 million). Additionally, the acute myeloid leukemia (AML) drug Xospata (gilteritinib) has reported a 13.8% increase in sales, reaching JPY 41.3 billion (USD 280 million). The newly launched Izervay (avacincaptad pegol) for geographic atrophy in the US has also seen a robust start.
Geographically, Astellas has recorded its most substantial growth in International Markets, with a 14% increase to JPY 118.8 billion. This growth was followed by Established Markets, including Europe and Canada, with a 12.5% rise to JPY 272.2 billion. The Greater China region reflected a 3.3% growth, amounting to JPY 67.3 billion, while the US market experienced a slight decline of -3.9%, reporting revenues of JPY 481.4 billion.- Flcube.com
